Multiple Myeloma Market Estimated at USD 21.3 Billion in 2023, Set for Strong Growth Through 2034

The Multiple Myeloma market size was estimated at approximately USD 21,300 million in 2023 and is projected to expand at a notable CAGR over the forecast period from 2020 to 2034. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Multiple Myeloma landscape.

In 2023, the total Multiple Myeloma market in the US was estimated at around USD 14,300 million, with growth expected through 2034. In the 4L+ treatment segment, approved CAR-T therapies, including ABECMA and CARVYKTI, were projected to generate approximately USD 828 million in the US in 2023, with further expansion anticipated as additional CAR-T therapies receive approval over the forecast period.

In 2023, the total incidence of Multiple Myeloma across the 7MM was estimated at around 75,000 cases, with figures expected to increase over the forecast period. Among the 7MM countries, the United States reported the highest incidence, followed by the EU4 and the UK. Within the EU4 and the UK, Germany had the largest number of new multiple myeloma cases in 2023, while Spain reported the fewest. The disease shows a higher prevalence in males, with over 50% of US cases diagnosed in men.

Data suggests that nearly 50% of newly diagnosed Multiple Myeloma patients are ineligible for transplant, while about one-third of eligible patients do not undergo the procedure. In 2023, the US had approximately 23,600 frontline transplant-ineligible and 9,200 transplant-eligible multiple myeloma patients.

DelveInsight’s report, “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Multiple Myeloma landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Multiple Myeloma market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Multiple Myeloma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Multiple Myeloma Market Forecast

Some of the key facts of the Multiple Myeloma Market Report: 

• The Multiple Myeloma market is anticipated to grow rapidly during the forecast period, driven by rising disease prevalence and increasing awareness. Additionally, the introduction of multiple late-stage pipeline products is expected to significantly reshape the market landscape and dynamics.
• Key Multiple Myeloma Companies: Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., CASI Pharmaceuticals, Sorrento Therapeutics, Johnson & Johnson Innovative Medicine, Bristol-Myers Squibb and Bluebird bio, Sanofi, and others
• Key Multiple Myeloma Therapies: Zevorcabtagene Autoleucel, Descartes 08, GC012F, CID-103, STI-1492, CARVYKTI (ciltacabtagene autoleucel) TALVEY (talquetamab), ABECMA, SARCLISA
• In terms of age-specific incidence, individuals aged 65 and above represent the largest proportion of multiple myeloma cases in the United States, accounting for over 70% of cases, followed by those aged 55–64 and 0–54 years.

Multiple Myeloma Overview

Multiple Myeloma is a type of blood cancer that originates in plasma cells, a kind of white blood cell found in the bone marrow. These abnormal plasma cells grow uncontrollably and produce excessive amounts of abnormal proteins, which can interfere with normal blood cell production and damage various organs.

Common symptoms include bone pain, fatigue, frequent infections, anemia, kidney dysfunction, and high calcium levels in the blood. The disease primarily affects older adults and progresses over time if not treated.

Get a Free sample for the Multiple Myeloma Market Forecast, Size & Share Analysis Report: 

Key Trends in Multiple Myeloma Therapeutics Market:

• Growth of Immunotherapies: Increasing adoption of CAR-T cell therapy, bispecific antibodies, and monoclonal antibodies is transforming treatment paradigms.
• Emergence of Targeted Therapies: Development of proteasome inhibitors, immunomodulatory drugs, and novel small molecules for more precise disease management.
• Combination Treatment Approaches: Rising use of multi-drug regimens to improve response rates and extend patient survival.
• Expansion of Early Diagnosis and Monitoring Tools: Advanced biomarkers and imaging technologies are enabling earlier detection and better treatment planning.
• Strong Clinical Pipeline: Ongoing late-stage clinical trials and R&D investments are accelerating the introduction of innovative therapies globally.

Multiple Myeloma Epidemiology

The Multiple Myeloma epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Multiple Myeloma Epidemiology Segmentation:

The Multiple Myeloma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Multiple Myeloma

Prevalent Cases of Multiple Myeloma by severity

Gender-specific Prevalence of Multiple Myeloma

Diagnosed Cases of Episodic and Chronic Multiple Myeloma

Download the report to understand which factors are driving Multiple Myeloma epidemiology trends @ Multiple Myeloma Epidemiology Forecast

Recent Development In The Multiple Myeloma Treatment Landscape:

• In March 2026, Johnson & Johnson (NYSE: JNJ), a global leader in therapies for Multiple Myeloma, announced that the U.S. Food and Drug Administration has approved the combination of TECVAYLI® (teclistamab-cqyv) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for treating adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior therapy, including a proteasome inhibitor and an immunomodulatory agent. This combination therapy works synergistically to activate the immune system and target myeloma cells expressing the BCMA protein. The approval introduces a promising new standard of care as early as the second-line setting and offers an innovative treatment option for the significant proportion of patients who experience disease relapse.
• In March 2026, The U.S. Food and Drug Administration has approved the combination of teclistamab (Tecvayli) and daratumumab hyaluronidase-fihj (Darzalex Faspro) for the treatment of adults with Relapsed or Refractory Multiple Myeloma (RRMM) who have previously undergone at least one line of therapy, including a proteasome inhibitor and an immunomodulatory agent.
• In March 2026, Johnson & Johnson (NYSE: JNJ), a global leader in multiple myeloma treatments, announced that the U.S. Food and Drug Administration (FDA) has approved a combination therapy of TECVAYLI (teclistamab-cqyv) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for adults with Relapsed or Refractory Multiple Myeloma (RRMM) who have previously received at least one line of treatment, including a proteasome inhibitor and an immunomodulatory agent. This combination works synergistically to stimulate and activate the immune system, enabling it to target and eliminate myeloma cells expressing the BCMA protein. The approval introduces a promising new treatment option that could potentially serve as a standard of care as early as second-line therapy, addressing the unmet needs of patients, particularly the nearly 40% who experience disease relapse.
• In September 2025, Lupin received U.S. FDA approval for its generic Lenalidomide Capsules (2.5–25 mg), a treatment for multiple myeloma and certain cases of myelodysplastic syndromes (MDS). The product, bioequivalent to Bristol-Myers Squibb’s Revlimid®, will be manufactured at Lupin’s Pithampur facility in India.
• In August 2025, Regeneron Pharmaceuticals highlighted its PD-1 inhibitor Libtayo as the standard of care for advanced cutaneous squamous cell carcinoma (CSCC), with ongoing research in melanoma and multiple myeloma.
• In May 2025, GSK announced that the CHMP of the EMA recommended approval of Blenrep for adults with relapsed or refractory multiple myeloma. The recommendation covers use with bortezomib and dexamethasone (BVd) for patients with at least one prior therapy, and with pomalidomide and dexamethasone (BPd) for those previously treated with lenalidomide. A final decision from the European Commission is expected in Q3 2025.
• In May 2025, Johnson & Johnson announced that the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 6-2 in favor of the benefit-risk profile of DARZALEX FASPRO® for treating high-risk smoldering multiple myeloma (HR-SMM). The FDA application for this indication was submitted in November 2024.
• In April 2025, Halozyme announced that the European Commission approved an indication extension for subcutaneous DARZALEX® (daratumumab) co-formulated with ENHANZE®. The new approval allows its use with bortezomib, lenalidomide, and dexamethasone (daratumumab-VRd) in newly diagnosed multiple myeloma patients.
• In March 2025, the FDA issued its first untitled letter to Edenbridge Pharmaceuticals (now Dexcel Pharma) over a promotional panel for Hemady. Triggered by a Bad Ad complaint, the FDA flagged omitted information and weak study data. Hemady, an oral dexamethasone formulation, provides 20 mg per tablet to reduce pill burden in multiple myeloma patients.
• In February 2025, Opna Bio announced that its oral small molecule inhibitor, OPN-6602, received FDA Orphan Drug designation for multiple myeloma. OPN-6602 targets E1A-binding protein (EP300) and CREB-binding protein (CBP).

Multiple Myeloma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Myeloma market or expected to get launched during the study period. The analysis covers Multiple Myeloma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Multiple Myeloma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Multiple Myeloma Therapies and Key Companies

• Zevorcabtagene Autoleucel: Carsgen Therapeutics
• Descartes 08: Cartesian Therapeutics
• GC012F: Gracell Biotechnology Shanghai Co., Ltd.
• CID-103: CASI Pharmaceuticals
• STI-1492: Sorrento Therapeutics
• CARVYKTI (ciltacabtagene autoleucel): Johnson & Johnson Innovative Medicine
• TALVEY (talquetamab): Johnson & Johnson Innovative Medicine
• ABECMA: Bristol-Myers Squibb and Bluebird bio
• SARCLISA: Sanofi

Discover more about therapies set to grab major Multiple Myeloma market share @ Multiple Myeloma Treatment Landscape

Multiple Myeloma Market Drivers

• Rising Disease Incidence: Increasing prevalence of Multiple Myeloma, especially among the aging population, is driving demand for advanced therapies.
• Advancements in Targeted & Immunotherapies: Growth of CAR-T cell therapy, monoclonal antibodies, and bispecific antibodies is transforming treatment outcomes.
• Strong Pipeline and Ongoing Clinical Trials: Continuous innovation and late-stage pipeline assets are expanding therapeutic options.
• Improved Diagnostic Techniques: Early detection through advanced imaging and biomarker-based tests is boosting treatment rates.
• Favorable Regulatory Support: Accelerated approvals and orphan drug incentives are encouraging pharmaceutical investments.

Multiple Myeloma Market Barriers

• High Cost of Advanced Therapies: CAR-T therapies and biologics are expensive, limiting accessibility for many patients.
• Treatment Resistance and Relapse: High relapse rates and drug resistance remain major clinical challenges.
• Adverse Side Effects: Toxicities associated with chemotherapy and immunotherapies can affect patient compliance.
• Limited Access in Emerging Markets: Inadequate healthcare infrastructure and reimbursement issues hinder market penetration.
• Complex Treatment Regimens: Multi-line therapies and combination treatments can complicate disease management.

Scope of the Multiple Myeloma Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Multiple Myeloma Companies: Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., CASI Pharmaceuticals, Sorrento Therapeutics, Johnson & Johnson Innovative Medicine, Bristol-Myers Squibb and Bluebird bio, Sanofi, and others
• Key Multiple Myeloma Therapies: Zevorcabtagene Autoleucel, Descartes 08, GC012F, CID-103, STI-1492, CARVYKTI (ciltacabtagene autoleucel) TALVEY (talquetamab), ABECMA, SARCLISA, and others
• Multiple Myeloma Therapeutic Assessment: Multiple Myeloma current marketed and Multiple Myeloma emerging therapies
• Multiple Myeloma Market Dynamics: Multiple Myeloma market drivers and Multiple Myeloma market barriers 
• Multiple Myeloma Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Multiple Myeloma Unmet Needs, KOL’s views, Analyst’s views, Multiple Myeloma Market Access and Reimbursement 

To know more about Multiple Myeloma companies working in the treatment market, visit @ Multiple Myeloma Clinical Trials and Therapeutic Assessment

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.